GlassScriptPhysician profile
Crystal M Weems
NPI 1225517253
$3,896.88
in general payments reported to CMS, 2019-2025
34 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,193 · 2022: $492 · 2023: $1,096 · 2024: $1,004 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,211.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $882.72 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $380.54 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $373.20 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $231.61 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.79 | 2021-2024 | Xifaxan |
| Amgen INC. | $209.88 | 2021-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $184.28 | 2022-2024 | |
| Novo Nordisk INC | $174.73 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $148.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.49 | 2021-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.79 | 2021-2023 | Tradjenta |
| Vanda Pharmaceuticals INC. | $90.82 | 2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $88.04 | 2024 | Auvelity |
| Exact Sciences Corporation | $78.56 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $77.44 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $77.22 | 2021-2024 | |
| Corium, LLC | $54.47 | 2023 | Adlarity |
| Boston Scientific Corporation | $45.81 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.47 | 2022 | |
| Esperion Therapeutics, INC. | $40.90 | 2021 | |
| Radius Health, INC. | $27.97 | 2024 | Tymlos |
| Phathom Pharmaceuticals, INC. | $26.66 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $26.30 | 2021 | |
| Nevro Corp. | $24.81 | 2021 | |
| Dexcom, INC. | $24.73 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $23.96 | 2021 | |
| Daiichi Sankyo INC. | $21.46 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.09 | 2024 | Rexulti |
| Almatica Pharma LLC | $18.40 | 2021 | |
| Merck Sharp & Dohme LLC | $16.33 | 2023 | Verquvo, Steglatro, Belsomra |
| Astellas Pharma US INC | $16.16 | 2023 | Veozah |
| Xeris Pharmaceuticals, INC. | $13.10 | 2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $12.46 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Weems listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.